Lifestyle modification program

Studies of lifestyle modification program in people

35 studies gave lifestyle modification program to people and measured what changed

What changedDesignPeopleSource

down: Decreases PhenoAge-4.9 vs +1.3 years; between-group p < 0.001

down: Decreases body weight-5.7 kg between-group

no change: Has no effect on GDF-15

Randomized trial6 months181 peopleBothmean 50.8 ± 10.9 yearsMidlife adults; Patient cohortsFrontiers in aging, Sep 10, 2026

up: Improves dietary adherencer = 0.65, p = 0.006

down: Decreases perceived stressr = 0.58, p = 0.013

up: Improves quality of lifer = 0.55, p = 0.018

Trial16 weeks18 peopleBothmedian age 47 yearsMidlife adultsAcademic Journal of Health Sciences, Aug 26, 2026

up: Improves Physical Performance Testmean difference 2.5 points, 95% CI 1.2-3.8

Randomized trial6 months114 peopleBoth65-85 yearsOlder adults; Patient cohortsThe lancet. Healthy longevity, Jul 30, 2026

down: Decreases body mass index

up: Improves physical function

up: Improves health-related quality of life

Randomized trialthree months200 peopleWomen50-58 yearsMidlife adults; Postmenopausal womenElectronic Journal of General Medicine, Jun 1, 2026

down: Decreases menopausal symptoms

Randomized trial6 months120 peopleWomen40–42 yearsMidlife adults; perimenopausal womenInternational Journal of Drug Delivery Technology, Apr 11, 2026

down: Lowers the risk of type 2 diabetes

down: Decreases fasting blood glucose

down: Decreases BMI

Randomized trial18-month320 peoplewomenWomen with a history of GDM in rural areas of Hunan provinceBMC public health, Mar 14, 2026

down: Decreases HbA1c7.9% (7.0-8.7) vs 8.6% (7.6-9.8), p<0.001

Randomized trial3 months353 peopleType 2 diabetesmedRxiv, Mar 9, 2026

up: Improves healthy behavior73.8% compared to 26.2%, p < 0.001

no change: Has no effect on glycemic controlp = 0.061

Randomized trial22 weeksType-2 Diabetes MellitusResearch Square, Mar 2, 2026

up: Improves visual evoked potential

down: Decreases retinal nerve fiber layer thickening

no change: Has no effect on central macula thickness

Trial12 weeks75 peopleType 2 diabetes mellitus with diabetic retinopathyThe Journal of the Association of Physicians of India, Mar 1, 2026

up: Improves diet qualityOR = 4.7, 95% CI = 1.2–17.8

Randomized trial3 months220 peopleBothmean age 48 ± 10 yearsMidlife adults; precontemplation/contemplation stage in adults at high risk for diabetesResearch Square, Feb 27, 2026

down: Decreases body mass index

down: Decreases muscle massminimal loss

Trialsix follow-up visits44 peopleHospitalized psychiatric patients treated with antipsychotic and/or antidepressant drugsMediterranean Journal of Nutrition and Metabolism, Feb 24, 2026

down: Decreases MFN2 degradation products

down: Decreases body mass index

Trial12 months43 peopleBotholder adultsOlder adults; in metabolically unhealthy obesity after 12 monthsNutrients, Feb 1, 2026

up: Improves health and related outcomes

Trial8 months39 peoplePatient cohortsResearch Square, Jan 16, 2026

down: Decreases cardiovascular risk8.03% to 6.71%

down: Decreases body weight73.1 to 71.7 kg

down: Decreases physical inactivity60% to 39%

Trial16-week100 peopleBothGeneral populationJournal of clinical medicine, Jan 13, 2026

up: Increases prediabetes remission45.9 % vs 6.3 %; RR 7.04, 95 % CI 5.12-10.06

down: Decreases fasting plasma glucose-5.2 mg/dL

down: Decreases body weight-3.7 kg

Randomized trial12 months1,092 peopleWomen30-60 yearsMidlife adults; isolated impaired fasting glucoseDiabetes research and clinical practice, Jan 13, 2026

up: Improves DAS28-CRPmean change -1.0 ± SD 0.9

up: Improves metabolic syndrome Z-scoremean change -1.6 ± SD 2.4

Trial1.9 ± 0.5 years14 people78.6% were women68.9 ± 5.0 years oldAdults with obesity and rheumatoid arthritisACR open rheumatology, Dec 1, 2025

up: Improves handgrip strength

down: Decreases HbA1c

Randomized trial12-week31 peopleMost participants were femalemidlifeHealthy adults born between 1955 and 1963 who are part of the Korean baby boomer generationNutrients, Sep 20, 2025

up: Improves hand grip strengthP = 0.039

up: Improves quality of lifeP = 0.019

up: Improves social participationP = 0.026

Randomized trial12-mo93 peopleMenolder adultsOlder adults; normal weight groupNutrition (Burbank, Los Angeles County, Calif.), Jun 13, 2025

up: Improves physical function+25.5 m, 95%CI (3.2–47.9)

up: Improves knee extension strength+19 N, 95%CI (1–38)

up: Increases dietary protein intake+15 g/day, 95%CI (1–28)

Randomized trialsix-month period65 peoplepredominantly female (91%)mean age of 65 years (SD = 7)Non-Western migrant backgrounds, aged 55 years or olderThe journal of nutrition, health & aging, May 22, 2025

down: Decreases metabolic syndrome

down: Decreases blood glucose

down: Decreases blood pressure

Trial10 days95 people85 women out of 95 participants18-70 yearsVolunteersJournal of lifestyle medicine, Feb 28, 2025

down: Decreases systolic blood pressuremedian from 173.86 mmHg to 142.53 mmHg

no change: Has no effect on diastolic blood pressure

Trial106 peopleMidlife adults; Older adults; Patient cohortsAfrican journal of reproductive health, Oct 31, 2024

no change: Has no effect on distal symmetrical polyneuropathyILS 21.5%, metformin 21.5%, placebo 21.9%

down: Lowers the risk of distal symmetrical polyneuropathy17.4% (95% CI 3.0, 29.3) lower OR

Randomized trialapproximately 21 years after DPP randomization3,234 people≥25 years oldMidlife adults; Older adults; at high risk for diabetesDiabetes care, Mar 19, 2024

up: Raises the risk of mortalityRR 1.28 (+28%)

Review of trialsmedian study duration for all studies was 6 months, with the shortest intervention period lasting 2 h (0.00274 months) and the longest intervention lasting 10 years (120 months)minimum age of 60 yearsParticipants in U.S.-based lifestyle clinical trials for cognitive healthContemporary clinical trials communications, Feb 15, 2024

down: Decreases body weight-3.7 ± 4 kg, P < 0.001

up: Increases telomere length+0.25 ± 0.9 vs -0.07 ± 1.0 relative units, p = 0.036

down: Lowers the risk of telomere shorteningOR = 0.17, 95%CI: 0.05-0.64, p = 0.008

Randomized trial3 years317 peopleWomenmean age, 65.8 ± 4.98 yearsOlder adults; Patient cohortsClinical nutrition (Edinburgh, Scotland), Jul 10, 2023

no change: Has no effect on body weight-0.17%, 95% CI -1.04, 0.71

down: Decreases HbA1cmean difference = -0.24%, Hedges' g = 0.23

Randomized trialapproximately 7 to 9 months494 peopleBothmean age of 68 yearsOverweight or obese community club membersPLoS medicine, Apr 15, 2022

up: Improves dietary habitsb=0.96

Trial13-month298 peopleBothaverage 68.0 years oldAdults aged 60–75 with overweight or obesityJournal of applied gerontology : the official journal of the Southern Gerontological Society, Feb 2, 2022

down: Decreases fat mass

Trial12 months158 people36 men (22.8%) and 122 (77.2%) women72.21 ± 5.04 yearsMetabolically healthy elderly population with overweight/obesityInternational journal of environmental research and public health, Nov 13, 2021

up: Increases physical activity

down: Decreases anxiety symptoms

up: Improves daily functioning

Randomized trial10 weeks21 peoplePatients seen by the geriatricians in primary care and the behavioral neurology service at Mayo Clinic Arizona who expressed cognitive concerns but had no evidence of objective cognitive declineBrain sciences, Sep 30, 2021

down: Decreases body weight

up: Improves muscle strength

down: Decreases dietary fat intake

Trial6 monthsBoth57-74 yearsMidlife adults; Older adults; inactive adults with obesity and elevated cardiovascular disease riskPloS one, Aug 25, 2021

up: Improves physical functioning

Trial1 year111 peoplemean age, 82.37 yearsOlder adults; The oldest old; institutionalized older adults with and without dementiaInternational journal of environmental research and public health, Jul 17, 2021

down: Decreases body weight3.22 ± 3.43 kg vs 0.03 ± 2.51 kg; 41.1% achieved 5% weight loss

down: Decreases cardiometabolic risk factors

Randomized trial24 months480 peopleBotholder adultsOlder adults; obese older adults, versus usual careExperimental gerontology, Oct 20, 2019

down: Lowers the risk of slow gait speedadjusted OR 0.84 [0.71 to 0.99]

up: Improves gait speedadjusted mean difference [95% CI]: 0.019 [0.007 to 0.031] m/s, p = .002

up: Improves physical function0.037 [0.011 to 0.063], p = .005

Randomized trialapproximately 11 years postrandomization and 1.5 years after the intervention was stopped3,783 peopleaged 45-76 years at enrollmentMidlife adults; Older adults; type 2 diabetes, overweight and obeseThe journals of gerontology. Series A, Biological sciences and medical sciences, Oct 21, 2017

down: Decreases malondialdehyde5.28±0.52 vs 4.48±0.69 m mol/ml

down: Decreases systolic blood pressure

down: Decreases fasting lipids

Trialthree months74 peopleBoth60 to 80 yearsOlder adultsJournal of clinical and diagnostic research : JCDR, Sep 1, 2016

down: Decreases body weight

down: Decreases LDL cholesterol

up: Increases adiponectin

Trial8 weeksWomen8-week program in obese female college studentsAdvances in experimental medicine and biology, Jan 1, 2013

down: Decreases type 2 diabetes incidence58% reduction (95% CI 48 to 66%) versus placebo

Randomized trialaverage follow-up 2.8 years3,234 peopleBothmean 51 yearsMidlife adultsThe New England journal of medicine, Feb 7, 2002